Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis
Ollech J, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer P, Christensen B, Pekow J, Dalal S, Sakuraba A, Cohen R, Rubin D. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019, 51: 637-643. PMID: 31875986, DOI: 10.1111/apt.15616.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedCalcineurin InhibitorsColitis, UlcerativeDrug Administration ScheduleDrug ResistanceFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexSteroidsTreatment OutcomeYoung AdultConceptsSevere steroid-refractory ulcerative colitisSteroid-refractory ulcerative colitisCalcineurin inhibitorsInduction therapyMaintenance therapyUlcerative colitisVedolizumab initiationMedian timeWeek 14Colectomy-free survival ratesSevere steroid-refractory colitisColectomy-free survivalSteroid-refractory colitisVedolizumab maintenance therapyInduction of remissionSerious adverse eventsSevere ulcerative colitisRetrospective observational studyEnd of inductionBiochemical remissionVedolizumab discontinuationClinical remissionPrimary endpointSecondary endpointsAdult patients